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A B S T R A C T
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease, mainly aﬀecting the motor neurons
(MNs) and without eﬀective therapy. Drug screening is hampered by the lack of satisfactory experimental and
pre-clinical models. Induced pluripotent stem cells (iPSCs) could help to deﬁne disease mechanisms and ther-
apeutic strategies as they could be diﬀerentiated into MNs, otherwise inaccessible from living humans. In this
study, given the seminal role of TDP-43 in ALS pathophysiology, MNs were obtained from peripheral blood
mononuclear cells-derived iPSCs of an ALS patient carrying a p.A382T TARDBP mutation and a healthy donor.
Venous samples were preferred to ﬁbroblasts for their ease of collection and no requirement for time consuming
extended cultures before experimentation. iPSCs were characterized for expression of speciﬁc markers, spon-
taneously diﬀerentiated into primary germ layers and, ﬁnally, into MNs. No diﬀerences were observed between
the mutated ALS patient and the control MNs with most of the cells displaying a nuclear localization of the TDP-
43 protein. In conclusion, we here demonstrated for the ﬁrst time that human TARDBP mutated MNs can be
successfully obtained exploiting the reprogramming and diﬀerentiation ability of peripheral blood cells, an
easily accessible source from any patient.
1. Introduction
An important limitation in the ﬁeld of neurodegenerative disorders
is the diﬃculty to translate information provided by preclinical re-
search into eﬀective new treatments for patients. This unmet need is
mainly due to the scarcity of adequate experimental models. This is
particularly true for amyotrophic lateral sclerosis (ALS), where motor
neurons (MNs) and other nervous tissues aﬀected by disease processes
are diﬃcult to obtain from alive patients. In addition, when post
mortem brain samples are available, diﬀerentiated neurons do not
anyway undergo cell division, resulting in a limited utility for in vitro
functional studies.
The majority of ALS patients present a sporadic form of the disease,
while around 10% are familial cases with>20 causative genes iden-
tiﬁed so far among which SOD1, C9ORF72, TARDBP and FUS represent
the main involved (Chen et al., 2013). Several transgenic animal models
have been developed in order to investigate the diﬀerent patho-
mechanisms of ALS and to test future possible therapies: the ﬁrst and
most commonly used was the human transgenic SOD1 mouse (Gurney
et al., 1994). Later, hemizygous and homozygous mice expressing wild-
type and mutated human TDP-43 (Stallings et al., 2010), (Xu et al.,
2010) together with mice carrying the C9ORF72 GGGGCC repeat ex-
pansion (Chew et al., 2015) were generated. Albeit animal models have
been useful for investigation of some ALS pathological mechanisms,
they recapitulate only partial aspects of the disease mostly reproducing
familial forms of ALS. Indeed, drug eﬀects in SOD1 transgenic mice
were rarely able to predict the same eﬃcacy in humans (Ludolph et al.,
2007), (Ludolph et al., 2010). This discrepancy may be explained by the
diversity in both structure and development of rodent and human
brains together with the absence of naturally occurring ALS in mice.
Consequently, animal models may not be the most adequate tool to
fully represent the various phenotypes of human ALS. Cellular model
systems, such as NSC-34 (Cashman et al., 1992), SH-SY5Y (Biedler
et al., 1973) or HEK293T (Graham et al., 1977) have also been widely
used and useful to study ALS pathomechanisms in vitro. However, they
are mostly tumor-derived or engineered cells, not completely
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mimicking the properties of primary neuronal cells. Recent innovative
in vitro model, such as induced pluripotent stem cells (iPSCs)
(Takahashi and Yamanaka, 2006), has represented a turning point in
the development of experimental disease models and can help to im-
prove current knowledge of the pathogenic mechanisms of ALS after
MN diﬀerentiation. In ALS, iPSCs have been generated from both mu-
tated and sporadic patients, extensively expanded in culture and dif-
ferentiated into cell types such as MNs and astrocytes (Jaiswal, 2017).
As the main hallmark of ALS is the progressive degeneration of spinal
cord MNs, their generation is essential for in vitro studies. MNs derived
from iPSCs have been shown to exhibit equivalent functional char-
acteristics of in vivo MNs: they express speciﬁc markers by im-
munostaining, are able to project axons and are responsive to glutamate
agonists. They therefore represent an ideal tool for modeling MN de-
generative diseases (Amoroso et al., 2013). The most widely used so-
matic cells for iPSCs generation are ﬁbroblasts (Gonzalez et al., 2011)
but several other cell types have been exploited, for example peripheral
blood cells (Huang, 2010). These cells present many advantages com-
pared to ﬁbroblasts as they do not need to be cultured in vitro for several
passages, avoiding the risk of genomic changes accumulation. In ad-
dition, peripheral blood collection is less invasive than skin biopsy.
The multifunctional RNA-binding protein TDP-43 is involved in
RNA metabolism including splicing, transcription and mRNA transport
(Ratti and Buratti, 2016). Its localization is primarily nuclear, however
the protein shuttles between nucleus and cytoplasm. In both familial
and sporadic ALS, as well as in frontotemporal dementia, pathological
TDP-43-positive cytoplasmic inclusions are observed in aﬀected brains
(Arai et al., 2006), (Neumann et al., 2006). Moreover, mutations in the
TDP-43-encoding gene TARDBP account for about 5% of familial and
1% of sporadic ALS cases and the missense p.A382T variant is the most
frequently occurring one in the Italian population (Corrado et al.,
2009). In this study we report, for the ﬁrst time, the reprogramming of
peripheral blood cells from an ALS patient carrying the TARDBP
p.A382T mutation into iPSCs. These iPSCs were fully characterized for
their pluripotency and successfully diﬀerentiated into MNs similarly to
healthy control-derived iPSCs.
2. Materials and methods
2.1. Participants and samples
This study was approved by the ethics committee of IRCCS Istituto
Auxologico Italiano. Written informed consent was obtained from the
participants. All research was performed in accordance with relevant
guidelines. We selected an ALS patient carrying the TARDBP p.A382T
mutation (see details in Table 1) and an unrelated healthy donor as
control. Both were females, 63 and 49 years old, respectively. PBMCs
were isolated from peripheral blood samples by density gradient cen-
trifugation on Ficoll-PaqueTM Plus (GE Healthcare, Chicago, IL, USA).
2.2. Generation of iPSCs
To generate iPSCs, 5× 105 PBMCs were seeded in a 24-well plate in
StemPro™-34 medium (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
supplemented with SCF (100 ng/ml), FLT-3 (100 ng/ml), IL-3 (20 ng/
ml) and IL-6 (20 ng/ml) cytokines (all from Peprotech, London, UK).
Half medium was daily changed and fresh cytokines added to the cell
suspension. After four days, transduction was performed using
CytoTune-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher
Scientiﬁc), by adding the Klf4, Oct4, Sox2 and c-Myc virus, following
manufacturer's instructions (KOS (Klf4–Oct3/4–Sox2) MOI=5, hcMyc
MOI= 5 and hKlf4 MOI=3). Three days later, transduced cells were
transferred on Mouse Embryonic Fibroblasts (MEF) feeder layer, and
grown in StemPro™-34 medium without the cytokines for four days.
Thereafter cultures were carried on in Essential 8 medium (Thermo
Fisher Scientiﬁc). Spent medium was daily replaced with fresh medium
and the culture vessels monitored for the emergence of iPSC colonies.
Twenty days post-transduction, colonies ready for transfer were in-
dividually picked and seeded onto Geltrex (Thermo Fisher Scientiﬁc)-
coated dishes. Colonies, passaged using an EDTA 0.5 μM solution, were
expanded in Essential 8 medium for at least six passages before being
characterized and diﬀerentiated.
2.3. Genotyping of patient-derived iPSCs
Genomic DNA was extracted from mutant iPSC using DNAzol
Reagent (Invitrogen). TARDBP exon 6 was ampliﬁed by PCR using the
following primers: FOR_tgcttgtaatctaagttttgttg and
REV_aaatttgaattcccaccattc. The amplicon was sequenced with BigDye
Terminator v3.1 Cycle Sequencing Kit on an ABI 3500 Genetic Analyzer
(Applied Biosystems) and compared with the reference sequence
NM_007375.3 GRCh37/hg19.
2.4. In vitro spontaneous diﬀerentiation of iPSCs
To test the in vitro spontaneous diﬀerentiation ability of the estab-
lished iPSCs, embryoid bodies (EBs) formation was performed by gently
resuspending iPSCs colonies in non-tissue culture-treated plates in
HuES medium (DMEM/F12, 20% knock-out serum replacement, 2 mM
L-glutamine, 10 U/ml penicillin, 10 μg/ml streptomycin, 0.1mM MEM
NEAA, 110 μM β-mercaptoethanol) (all from Thermo Fisher Scientiﬁc).
Medium was changed daily and after 7 days, EBs were collected and
plated on Geltrex-coated plates in Essential 8 medium. Expression of the
three germ layers speciﬁc markers was evaluated by immuno-
ﬂuorescence (βIII tubulin for ectoderm, desmin for mesoderm and
alpha-fetoprotein (AFP) for endoderm).
2.5. Motor neuron diﬀerentiation
A modiﬁed protocol from Amoroso et al. (Amoroso et al., 2013) was
used for MN diﬀerentiation. A schematic representation of the protocol
is shown in Fig. 2a. Brieﬂy, iPSCs were grown in a 100mm dish until
conﬂuence, harvested and placed into non-cell culture-treated dishes.
To obtain EBs, for the ﬁrst 2 days, cells were allowed to grow in sus-
pension in HuES medium supplemented with 20 ng/ml basic ﬁbroblast
growth factor (FGF) (Peprotech) and 20 μM Rho-associated kinase
(ROCK) inhibitor Y27632 (Selleckchem, Houston, TX, USA) in order to
enhance single cell survival. The third day, neuralization was induced
by the addition of 10 μM SB431542 and 0.2 μM LDN193189 (both from
Stemgent, Cambridge, NY, USA) to the cultures. The fourth day, EBs
were switched to neural induction medium (DMEM/F12, 2mM L-glu-
tamine, 10 U/ml penicillin, 10 μg/ml streptomycin, 0.1 mM MEM
NEAA, 2 μg/ml heparin (Sigma-Aldrich, Saint Louis, MO, USA), 1% N2
supplement (Thermo Fisher Scientiﬁc)), supplemented with 20 μM
ROCK inhibitor, 0.4 μg/ml ascorbic acid (AA) (Sigma-Aldrich), 1 μM
retinoic acid (RA) (Sigma-Aldrich), 10 ng/ml brain-derived neuro-
trophic factor (BDNF) (Peprotech). SB431542 and LDN193189 were
added until day 7 when cultures were supplemented with 1 μM
smoothened agonist (SAG) (Merck) and 0.5 μM purmorphamine (Pur)
(Sigma-Aldrich). EBs were grown for additional ten days with a
Table 1
Characteristics of the ALS TDP-43 p.A382T patient.
Clinical parameters Patient data
Dementia No (normal ECAS score)
ALS-FRS-R score 40/48 at diagnosis, 31/48 at blood sampling
Disease duration > 5 years
I MN involvement Yes
II MN involvement Yes
Onset symptoms Weakness in drawing head backwards (weakness of the
rectus capitis posterior muscle)
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medium change every alternate day. At day 17, EBs were dissociated
with 0.05% trypsin (Sigma-Aldrich) and plated on poly-lysine (Sigma-
Aldrich)/laminin (Thermo Fisher Scientiﬁc)-coated coverslips in 24-
well plates at a concentration of 5×105 cells/well. Cells were cultured
in neural diﬀerentiation medium (Neurobasal (Thermo Fisher Scien-
tiﬁc), 2 mM L-glutamine, 10 U/ml penicillin, 10 μg/ml streptomycin,
0.1 mM MEM NEAA, 1% N2 supplement), supplemented with 2% B27
(Thermo Fisher Scientiﬁc), 1 μg/ml laminin (Lam), 25 μM glutamate
(Glu) (Sigma-Aldrich), 0.4 μg/ml ascorbic acid, 10 ng/ml glial-derived
neurotrophic factor (GDNF) and 10 ng/ml ciliary neurotrophic factor
(CNTF) (both from Peprotech). MNs were allowed to diﬀerentiate for
10 days and ﬁnally ﬁxed for immunoﬂuorescence or recovered for RNA
extraction.
2.6. Reverse transcription-PCR
Total RNA from both iPSCs and iPSCs-derived MNs was isolated
using the TRIzol reagent (Thermo Fisher Scientiﬁc) following manu-
facturer's instructions and reverse transcribed into cDNA using Super
Script II reverse transcriptase (Thermo Fisher Scientiﬁc). Brieﬂy, a ﬁrst
incubation with ribonuclease inhibitor and DNAse was performed at
37 °C for 20min to remove contaminating DNA. Reverse transcription
was primed with Oligo(dt) primers and reaction incubated at 42 °C for
40min and 15min at 70 °C. Reverse transcription-PCR (RT-PCR) was
performed to identify the endogenous expression of pluripotency mar-
kers (Sox2, Oct3/4 and Nanog) in iPSCs and the MN speciﬁc marker
ChAT in iPSCs-derived MNs. The sequences of the primers are reported
in Table 2.
2.7. Immunoﬂuorescence
Cells were ﬁxed in 4% paraformaldehyde for 20min at room tem-
perature. Permeabilization was performed using 0.3% Triton X-100 and
ice-cold 100% methanol for nuclear staining. In order to avoid non-
speciﬁc binding of antibodies, ﬁxed cells were incubated for 20min in a
blocking solution (10% NGS in PBS) and thereafter, primary antibodies,
diluted in blocking solution, were added for 90min at 37 °C. Coverslips
were then washed twice with the blocking solution and cells stained
with Alexa 488 and Alexa 555 conjugated secondary antibodies for
45min at room temperature. For nuclei staining, 4′,6-Diamidino-2-
Phenylindole, Dihydrochloride (DAPI) 2 μg/ml was ﬁnally added for
5min at room temperature. Coverslips were rinsed with PBS, mounted
with FluorSave (Merck, Darmstadt, Germany) and images acquired at
confocal microscope (Nikon Eclipse C1, Minato, Japan). Primary anti-
bodies used are listed in Table 3.
3. Results
3.1. Generation of iPSCs from peripheral blood cells
Cellular reprogramming of peripheral blood samples from the ALS
patient (see Table1 for clinical characteristics) and the healthy control
was performed using the integration-free CytoTune-iPS Sendai
Reprogramming Kit. Three weeks after transduction, iPSC colonies
were grown to an appropriate size for transfer. The number of emerged
colonies was higher than 30 colonies/dish for both patient and control
sample. At least 6 colonies were individually picked and transferred
onto Geltrex coated dishes. Colonies were expanded for six passages
before characterization, diﬀerentiation and freezing.
3.2. Characterization and pluripotency of iPSCs
Cell morphology was typical of iPSCs, with a high nuclear to cyto-
plasmic ratio, forming compact multilayer colonies with deﬁned edges.
Their growth rate and morphology remained unchanged after several
passages. One clone from both mutant TDP-43 ALS patient and control
was further expanded and used for all the experiments. Genotyping
conﬁrmed mutation in the TARDBP iPSC line (Supplementary Fig. 1 a)
and both clones had a normal karyotype (Supplementary Fig. 1 b–c).
Both clones were positive for the expression of the widely used plur-
ipotency markers SSEA4, Tra-1-60 and Alkaline Phosphatase (AP) as
demonstrated by immunoﬂuorescence (Fig. 1a) and Sox2, Oct3/4 and
Nanog as shown by RT-PCR (Fig. 1b). The pluripotency of the two iPS
cell lines was further assessed through the formation of EBs and sub-
sequent spontaneous diﬀerentiation into the three germ layers. iPSC in
vitro diﬀerentiation ability was evaluated by immunoﬂuorescence,
showing the expression of AFP (endoderm), βIII tubulin (ectoderm) and
desmin (mesoderm) markers (Fig. 1c).
3.3. Motor neuron diﬀerentiation
Dissociated EBs plated on poly-lysine/laminin-coated coverslips
were cultured for 10 days to allow MN diﬀerentiation (Fig. 2a). Most of
the cells exhibited a typical neuronal morphology with long and
abundant axons as shown by βIII tubulin staining (Fig. 2b). Expression
of the MN speciﬁc marker HB9 was 15.5% in mutant TDP-43 patient-
derived MNs and 20.4% in control cells (Fig. 2b–d). In both samples,
80% of the cells were positive for the anti-neuroﬁlament antibody
SMI312 (Fig. 2c). Moreover, expression of the Choline acetyltransferase
(ChAT) enzyme was detected by RT-PCR in diﬀerentiated MNs from
both ALS patient and healthy donor (Fig. 2e).
3.4. Analysis of TDP-43 sub-cellular localization in iPSCs and iPSCs-
derived MNs
The RNA-binding protein TDP-43 is ubiquitously expressed and
primarily localizes in the nucleus. We ﬁrst examined TDP-43 sub-cel-
lular localization in the mutant TARDBP p.A382T and control iPSCs.
Our results demonstrated a prevalent nuclear distribution of TDP-43 in
Table 2
Primer sequences for pluripotency detection.
Gene Forward primer Reverse primer Size (bp) Ref.
Sox2 TTGCGTGAGTGTGGATGGGATTGGTG GGGAAATGGGAGGGGTGCAAAA GAGG 151 Takahashi et al., 2007
Oct3/4 GACAGGGGGAGGGGAGGAGCT AGG CTTCCCTCCAACCAGTTGCCCCA AAC 144 Takahashi et al., 2007
Nanog CAGCCCTGATTCTTCCACCAGTCC GTTCTGGAACCAGGTCTTCACCT G 244 -
ChAT TGAGTACTGGCTGAATGACATG AGTACACCAGAGATGAGGCT 144 Takahashi et al., 2007
Table 3
Immunocytochemistry primary antibodies for pluripotency and diﬀerentiations.
Primary antibody Supplier
Tra-1-60 (Podocalyxin) (TRA-1-60) Invitrogen (Carlsbad, CA, USA)
SSEA4 (eBioMC-813-70 (MC-813-70)) Invitrogen (Carlsbad, CA, USA)
Alpha-fetoprotein (AFP) Invitrogen (Carlsbad, CA, USA)
Alkaline phosphatase (AP) Abcam (Cambridge, UK)
Desmin (D33) DAKO (Santa Clara, CA, USA)
βIII tubulin (EP1569Y) Abcam (Cambridge, UK)
MNR2/HB9/Mnx1 (81.5C10) DSHB (Iowa City, IA, USA)
Pan-axonal neuroﬁlament marker (SMI312) Covance (Princeton, NJ, USA)
TDP-43 Proteintech (Rosemont, IL, USA)
P. Bossolasco et al. Stem Cell Research 30 (2018) 61–68
63
both patient and control iPSCs (Fig. 3a). As the neuropathological
hallmark of ALS is the cytoplasmic mislocalization and aggregation of
TDP-43 and its consequent nuclear depletion in disease-aﬀected cells,
we then investigated by immunoﬂuorescence whether iPSCs-derived
MNs from the patient displayed some of these pathological features. No
signiﬁcant diﬀerence was observed between the mutant TARDBP pa-
tient and the control MNs with most of the cells displaying a nuclear
localization of TDP-43 protein (Fig. 3b). A very small number of cells
presented evident cytoplasmic TDP-43 mislocalization in both samples
(2,1% in control MNs vs 2,9% in ALS patient MNs), while aggregates
were never observed (Fig. 3c).
4. Discussion
Primary causes and pathogenetic mechanisms of ALS are still mostly
unknown and adequate experimental systems are highly needed to
better understand the pathophysiology of this devastating disease.
Animal models and cell lines currently available have allowed to only
partially clarify the etiology of ALS and, clearly, the key issue has al-
ways been the diﬃculty to study the aﬀected tissues. Indeed, until 2007
human MNs could only be obtained in culture from spinal cord explants
(Quinn and De Boni, 1991) and dissociated cultures (Erkman et al.,
1989). Human MNs have been successfully isolated by im-
munomagnetic beads (Silani et al., 1998) with limited expansion and
survival capability. Moreover, spinal cord explant from living subjects
Fig. 1. Characterization of human iPSCs derived
from peripheral blood mononuclear cells of a
control (ctrl) and a mutated ALS TARDBP
p.A382T patient (pt). (a) Left panels are re-
presentative pictures of iPSC colonies. Scale bar,
100 μm. Immunostaining showing positivity for
the pluripotency markers SSEA-4, TRA-1-60 and
AP. Nuclei are stained with DAPI. Scale bar,
20 μm. (b) RT-PCR showing the expression of
pluripotency-associated genes Sox2, Oct3/4 and
Nanog. (c) In vitro iPSCs diﬀerentiation dis-
playing immunoreactivity for endodermal (AFP),
ectodermal (βIII tubulin) and mesodermal
(desmin) germ layer markers. Nuclei are stained
with DAPI. Scale bar, 10 μm.
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requires invasive surgical procedures hardly applicable in humans.
Thanks to the discovery of iPSCs by Takahashi et al. (Takahashi and
Yamanaka, 2006), (Takahashi et al., 2007), human MNs can now be
easily obtained potentially in unlimited quantity.
The aim of the present study is to report, for the ﬁrst time, iPSCs
reprogramming of peripheral blood mononuclear cells (PBMCs) of an
ALS patient carrying the TARDBP p.A382T mutation, and their suc-
cessful diﬀerentiation into MNs. Several authors have previously re-
ported that ﬁbroblast-derived iPSCs from both sporadic and familial
ALS patients may be diﬀerentiated into MNs displaying a disease-
Fig. 2. MN diﬀerentiation of control (ctrl) and ALS patient iPSCs (pt). (a) Schematic representation of MN diﬀerentiation protocol from iPSCs. Immunocytochemical
analysis of (b) HB9 (red) and βIII tubulin (green), and (c) SMI312 (red) ten days after EBs dissociation. Nuclei are stained with DAPI (blue). Scale bar, 10 μm. (d)
Quantitative analysis of HB9 positive cells. (e) RT-PCR showing the expression of the motor neuronal marker ChAT. Commercial human MNs were used as positive
control. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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speciﬁc phenotype (Almeida et al., 2013; Alves et al., 2015; Bilican
et al., 2012; Burkhardt et al., 2013; Dimos et al., 2008; Donnelly et al.,
2013; Egawa et al., 2012; Sareen et al., 2013). In addition, TARDBP
p.M337 V mutation seems not to aﬀect diﬀerentiation and maturation
of functional MNs from ﬁbroblast-derived iPSCs (Devlin et al., 2015).
So far diﬀerentiation of MNs from PBMC-derived iPSCs has only been
reported for a familial ALS patient carrying a FUS p.P525L mutation
(Liu et al., 2015) and cytoplasmic mislocalization as well as FUS protein
aggregation were observed.
In this study, we generated iPSCs starting from the PBMCs of an ALS
patient and we compared their characteristics to PBMCs-derived iPSCs
of a healthy donor as control. By using a Sendai reprogramming tech-
nology based on vectors expressing key genetic factors we have already
obtained several iPSC lines with high eﬃciency from ﬁbroblasts of both
ALS patients and healthy donors (data not shown). Moreover, this re-
programming methodology is safe as Sendai vectors do not integrate
into the host genome reducing the risk of genetic alterations in the host
cell (Seki et al., 2010). In order to fulﬁl clinical application criteria and
to maintain chromosome stability overtime, we grew iPSCs in a feeder-
free commercial medium able to avoid animal-derived constituents and
to perform long-term and stable serial culture passages without gen-
erating chromosomal abnormalities (Nakagawa et al., 2014).
We were able to obtain from both our peripheral blood samples
stable iPSC lines that were fully characterized. The morphology of the
iPSCs obtained was similar and displayed comparable expression of the
pluripotency-related markers (SSEA4, Tra-1-60, AP, Sox2, Oct3/4 and
Nanog). Similarly, no diﬀerences were observed concerning the spon-
taneous diﬀerentiation into the three germ lines indicating that the
presence of the TARDBP p.A382T mutation did not interfere with
pluripotency of the cells. iPSCs were then diﬀerentiated into MNs.
When analyzed by immunoﬂuorescence, no diﬀerences were observed
for the expression of the axonal neuroﬁlament marker SMI312 between
Fig. 3. TDP-43 expression in control (ctrl) and
patient (pt) iPSCs and MNs. (a) Immunostaining
of iPSCs showing TDP-43 nuclear expression.
Nuclei are stained with DAPI. Scale bar, 20 μm.
(b) Immunostaining of MNs with TDP-43 (red)
and SMI312 (green). SMI312 staining was per-
formed in order to visualize neuronal diﬀer-
entiated cells. Nuclei are stained with DAPI.
Scale bar, 10 μm. TDP-43 localization was
mainly nuclear, except for some cells with cy-
toplasmic positivity, as indicated by arrows (c).
The histogram shows a quantitative analysis of
the number of cells with TDP-43 mislocalization
in the cytoplasm. For each sample, ten micro-
scope ﬁelds displaying an average of 100 cells/
ﬁeld were analyzed. (For interpretation of the
references to colour in this ﬁgure legend, the
reader is referred to the web version of this ar-
ticle.)
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ALS patient and control iPSCs-derived MNs. Some variability was de-
tected in MN diﬀerentiation outcomes with little diﬀerent percentage of
HB9 positive cells. Indeed, the TDP-43 mutated patient and the healthy
control displayed 15.5% and 20.4% of HB9 positive cells, respectively.
Diﬀerent rates of diﬀerentiation have already been reported (Liu et al.,
2015), (Mitne-Neto et al., 2011) and it has been speculated that patient
age and diﬀerent mutations may inﬂuence the percentage of fully dif-
ferentiated MNs (Liu et al., 2015). In our study, the slight discrepancy
may be explained by a random eﬀect or by the diﬀerent age of the
subjects as the control was 14 years younger than the patient.
We ﬁnally investigated whether the mutant MNs recapitulate in
vitro, without additional stressors, key aspects of ALS such as TDP-43
protein mislocation and aggregation. We found that TDP-43 localiza-
tion was predominantly nuclear and only a very small percentage of
cells displayed a cytoplasmatic staining with no aggregates and no
diﬀerences between the mutant and wild-type. The physiological levels
of cytoplasmic localization of the TDP-43 protein was 2,1% in control vs
2,9% in ALS patient. Previous studies reported a cell autonomous pa-
thological phenotype of TARDBP mutated MNs diﬀerentiated from ﬁ-
broblast-derived iPSCs. In particular, in MNs derived from a TARDBP
p.M337 V mutated patient, predominantly nuclear TDP-43 was ob-
served, albeit punctate TDP-43 staining in the soma and cell processes
was frequently observed (Bilican et al., 2012). In another study, MNs
were diﬀerentiated from iPSCs of ALS patients carrying p.Q343R,
p.M337 V, or p.G298S TDP-43 mutations and the authors demonstrated
that TDP-43 was distributed in both the nucleus and the cytoplasm,
with TDP-43 forming preinclusion-like aggregates in the cytoplasm
(Egawa et al., 2012). Our diﬀerent ﬁndings may be explained by a
clonal or patient-to-patient variability, or by the diﬀerent mutation
considered. More recently in agreement with our results, no diﬀerence
was observed in the number of cytoplasmic puncta in MNs derived from
TARDBP p.M337 V mutated patient compared to a control (Seminary
et al., 2018) and no TDP43 mislocalization or aggregation formation
was reported in iPSCs-derived MNs from a p.G294 V mutated patient
(Kreiter et al., 2018). Further investigations with a higher number of
patients carrying the p.A382T mutation and eventually other mutations
are required to conﬁrm our result.
In conclusion, we established integration-free iPSCs from the per-
ipheral blood of an ALS patient carrying the TARDBP p.A382T muta-
tion. We demonstrated that these cells were morphologically and phe-
notypically comparable to those obtained from a healthy donor,
displaying the same ability to diﬀerentiate into MNs. In addition, no
TDP-43 aggregation or abnormal cytoplasmic distribution were ob-
served. Given the easy access of peripheral blood, iPSCs-derived MNs
may be potentially generated from any patient and the establishment of
an ALS-MNs cell bank will greatly help to explore the variety of pa-
thogenic mechanisms of the disease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2018.05.009.
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